Immunology

Corixa Corp. signs research, development, and license agreement

Published in Vaccine Weekly, October 8th, 2003

InNexus Biotechnology, Inc., (IXS), a monoclonal antibody-development company, and Corixa Corp. (CRXA), a developer of immunotherapeutic products, announced that the companies have entered into an antibody research, development, and license agreement.

The companies will develop lead antibody candidates combining InNexus' SuperAntibody Technology (SAT) with up to four antibodies from Corixa's therapeutic antibody development program.

InNexus' SAT technology can increase the binding strength of monoclonal antibodies, which allows them to cross-link their target antigen. This process can trigger "apoptosis," or cell suicide, or the enhancement of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-10-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry